Combined gene expression and genomic profiling define two intrinsic molecular subtypes of urothelial carcinoma and gene signatures for molecular grading and outcome

Cancer Research

Volumn 70, Issue 9, 2010, Pages 3463-3472

  Lindgren, David ^a   Frigyesi, Attila ^b   Gudjonsson, Sigurdur ^b   Sjödahl, Gottfrid ^a   Hallden, Christer ^c   Chebil, Gunilla ^d   Veerla, Srinivas ^a   Ryden, Tobias ^a   Månsson, Wiking ^b   Liedberg, Fredrik ^e   Höglund, Mattias ^a  

^a LUND UNIVERSITY   (Sweden)

^b LUND UNIVERSITY HOSPITAL   (Sweden)

^c Malmö University Hospital   (Sweden)

^d HELSINGBORG HOSPITAL   (Sweden)

^e Vaxjo Hospital   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN DEPENDENT KINASE INHIBITOR 2A; FIBROBLAST GROWTH FACTOR RECEPTOR 3; GENOMIC DNA; K RAS PROTEIN; PROTEIN; PROTEIN P53; TSC1 PROTEIN; UNCLASSIFIED DRUG;

ACCURACY; ARTICLE; BLADDER CANCER; CANCER GRADING; CLUSTER ANALYSIS; COMPARATIVE GENOMIC HYBRIDIZATION; GENE EXPRESSION PROFILING; GENE MUTATION; GENOMIC INSTABILITY; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; MUTATIONAL ANALYSIS; ONCOGENE H RAS; ONCOGENE N RAS; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROGNOSIS; URINARY TRACT CARCINOMA; UROTHELIUM CARCINOMA;

1-PHOSPHATIDYLINOSITOL 3-KINASE; ALGORITHMS; COMPARATIVE GENOMIC HYBRIDIZATION; GENE EXPRESSION PROFILING; GENES, P16; GENES, P53; GENES, RAS; GENOMICS; HUMANS; NEOPLASM STAGING; RECEPTOR, FIBROBLAST GROWTH FACTOR, TYPE 3; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEINS; URINARY BLADDER NEOPLASMS;

EID: 77951756330     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-09-4213     Document Type: Article

References (49)

1. Fadl-Elmula I. Chromosomal changes in uroepithelial carcinomas. Cell Chromosome 2005;4:1-5.
2. Höglund M, Säll T, Heim S, et al. Identification of cytogenetic subgroups and karyotypic pathways in transitional cell carcinoma. Cancer Res 2001;61:8241-8246
3. Richter J, Jiang F, Gorog JP, et al. Marked genetic differences between stage pTa and stage pT1 papillary bladder cancer detected by comparative genomic hybridization. Cancer Res 1997;57:2860-2864
4. Richter J, Beffa L, Wagner U, et al. Patterns of chromosomal imbalances in advanced urinary bladder cancer detected by comparative genomic hybridization. Am J Pathol 1998;153:1615-1621 (Pubitemid 28509919)
5. Zhao J, Richter J, Wagner U, et al. Chromosomal imbalances in non-invasive papillary bladder neoplasms (pTa). Cancer Res 1999;59: 4658-4661 (Pubitemid 29428972)
6. Veltman JA, Fridlyand J, Pejavar S, et al. Array-based comparative genomic hybridization for genome-wide screening of DNA copy number in bladder tumors. Cancer Res 2003;63:2872-2880 (Pubitemid 36667159)
7. Blaveri E, Brewer JL, Roydasgupta R, et al. Bladder cancer stage and outcome by array-based comparative genomic hybridization. Clin Cancer Res 2005;11:7012-7022 (Pubitemid 41428761)
8. Heidenblad M, Lindgren D, Jonson T, et al. Tiling resolution array CGH and high density expression profiling of urothelial carcinomas delineate genomic amplicons and candidate target genes specific for advanced tumors. BMC Med Genomics 2008;1:3-15.
9. Chapman EJ, Harnden P, Chambers P, et al. A comprehensive analysis of CDKN2A status in micro dissected urothelial cell carcinoma reveals potential haploinsufficiency, a high frequency of homozygous co-deletion and associations with clinical phenotype. Clin Cancer Res 2005;11:5740-5747
10. Oeggerli M, Tomovska S, Schraml P, et al. E2F3 amplification and over expression is associated with invasive tumor growth and rapid tumor cell proliferation in urinary bladder cancer. Oncogene 2004;23: 5616-5623 (Pubitemid 39093039)
11. Feber A, Clark J, Goodwin G, et al. Amplification and overexpression of E2F3 in human bladder cancer. Oncogene 2004;23:1627-1630
12. Knowles MA. Molecular subtypes of bladder cancer: Jekyll and Hyde or chalk and cheese? Carcinogenesis 2006;27:361-373
13. Billerey C, Chopin D, Aubriot-Lorton MH, et al. Frequent FGFR3 mutations in papillary non-invasive bladder (pTa) tumors. Am J Pathol 2001;158:1955-1959.
14. Wu XR. Urothelial tumorigenesis: a tale of divergent pathways. Nat Rev Cancer 2005;5:713-725
15. Blaveri E, Simko JP, Korkola JE, et al. Bladder cancer outcome and subtype classification by gene expression. Clin Cancer Res 2005;11: 4044-4045
16. Dyrskjøt L, Kruhoffer M, Thykjaer T, et al. Gene expression in the urinary bladder: a common carcinoma in situ gene expression signature exists disregarding histopathological classification. Cancer Res 2004;64:4040-4048
17. Dyrskjøt L, Thykjaer T, Kruhøffer M, et al. Identifying distinct classes of bladder carcinoma using microarrays. Nat Genet 2003;33:90-96
18. Dyrskjøt L, Zieger K, Kruhøffer M, et al. A molecular signature in superficial bladder carcinoma predicts clinical outcome. Clin Cancer Res 2005;11:4029-4036
19. Kim JH, Tuziak T, Hu L, et al. Alterations in transcription clusters underlie development of bladder cancer along papillary and nonpapillary pathways. Lab Invest 2005;85:532-549
20. Lindgren D, Liedberg F, Andersson A, et al. Molecular characterization of early-stage bladder carcinomas by expression profiles, FGFR3 mutation status, and loss of 9q. Oncogene 2006;25:2685-2696
21. Mor O, Nativ O, Stein A, et al. Molecular analysis of transitional cell carcinoma using cDNA microarray. Oncogene 2003;22: 7702-7710
22. Sanchez-Carbayo M, Socci ND, Lozano J, et al. Defining molecular profiles of poor outcome in patients with invasive bladder cancer using oligonucleotide microarrays. J Clin Oncol 2006;24:778-789
23. Thykjaer T, Workman C, Kruhøffer M, et al. Identification of gene expression patterns in superficial and invasive human bladder cancer. Cancer Res 2001;61:2492-2499
24. Wild PJ, Herr A, Wissmann C, et al. Gene expression profiling of progressive papillary noninvasive carcinomas of the urinary bladder. Clin Cancer Res 2005;11:4415-4429
25. Stransky N, Vallot C, Reyal F, et al. Regional copy number-independent deregulation of transcription in cancer. Nat Genet 2006;38:1386-1396
26. Dyrskjøt L, Zieger K, Real FX, et al. Gene expression signatures predict outcome in non-muscle-invasive bladder carcinoma: a multicenter validation study. Clin Cancer Res 2007;13:3545-3551
27. Saal LH, Troein C, Vallon-Christersson J, et al. BioArray Software Environment (BASE): a platform for comprehensive management and analysis of microarray data. Genome Biol 2003;3:SOFTWARE0003.
28. Yang YH, Dudoit S, Luu P, et al. Normalization for cDNA microarray data: a robust composite method addressing single and multiple slide systematic variation. Nucleic Acids Res 2002;30:e15.
29. Andersson A, Edén P, Lindgren D, et al. Gene expression profiling of leukemic cell lines reveals conserved molecular signatures among subtypes with specific genetic aberrations. Leukemia 2005;19: 1042-1050
30. Saeed AI, Sharov V, White J, et al. TM4: a free, open-source system for microarray data management and analysis. Biotechniques 2003; 34:374-378
31. The Swegene DNA micro array resource center. Available from: http://www-lth.se/sciblu.
32. Gene Expression Omnibus. Available from: http://www.ncbi.nlm.nih.gov/geo/ .
33. Journal of Clinical Oncology home page. Available from: http://www.jco.org.
34. Array Express home page. Available from: http://www.ebi.ac.uk/microarray- as/ae/.
35. Clinical Cancer Research home page. Available from: http://clincancerres. aacrjournals.org/.
36. Subramanian A, Tamayo P, Mootha VK, et al. Gene Set Enrichment Analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A 2005;102: 15545-15550 (Pubitemid 41528093)
37. Molecular Signatures Database. Available from: http://www.broadinstitute. org/gsea/msigdb/index.jsp.
38. Bild AH, Yao G, Chang JT, et al. Oncogenic pathway signatures in human cancers as a guide to targeted therapies. Nature 2006;439: 353-357 (Pubitemid 43128862)
39. Carter SL, Eklund AC, Kohane IS, et al. A signature of chromosomal instability inferred from gene expression profiles predicts clinical outcome in multiple human cancers. Nat Genet 2006;38: 1043-1048
40. Hosack DA, Dennis G, Jr., Sherman BT, et al. Identifying biological themes within lists of genes with EASE. Genome Biol 2003;4:P4.
41. Statnikov A, Tsamardinos I, Dosbayev Y, et al. GEMS: a system for automated cancer diagnosis and biomarker discovery from micro array gene expression data. Int J Med Inform 2005;74:491-493 (Pubitemid 41021913)
42. The CHORI BACPAC resources. Available from: http://bacpac.chori.org/ genomicRearrays.php.
43. Jönsson G, Staaf J, Olsson E, et al. High-resolution genomic profiles of breast cancer cell lines assessed by tiling BAC array comparative genomic hybridization. Genes Chromosomes Cancer 2007;46:543-558 (Pubitemid 46649569)
44. The UCSC genome browser. Available from: http://www.genome.ucsc.edu/.
45. Staaf J, Jönsson G, Ringnér M, et al. Normalization of array-CGH data: influence of copy number imbalances. BMC Genomics 2007; 8:382.
46. Venkatraman ES, Olshen AB. A faster circular binary segmentation algorithm for the analysis of array CGH data. Bioinformatics 2007; 23:657-663 (Pubitemid 46554715)
47. Jin Y, Stewénius Y, Lindgren D, et al. Distinct mitotic segregation errors mediate chromosomal instability in aggressive urothelial cancers. Clin Cancer Res 2007;13:1703-1712
48. Crawford NP, Qian X, Ziogas A, et al. Rrp1b, a new candidate susceptibility gene for breast cancer progression and metastasis. PLoS Genet 2007;3:e214.
49. Crawford NP, Ziogas A, Peel DJ, et al. Germline polymorphisms in SIPA1 are associated with metastasis and other indicators of poor prognosis in breast cancer. Breast Cancer Res 2006;8:R16.